← All trials
NCT03820414
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2019
- Primary completion
- May 4, 2020
- Completion date
- Sep 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Curevo IncLead sponsor
- Immune DesignCollaborator
- Immune DesignStudy director
- Green Cross CorporationCollaborator
- The Center for Pharmaceutical ResearchOverall official - principal investigator
- Mogam Biotechnology Research InstituteCollaborator
- Curevo IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.